Finland Times

Thursday, 28 March, 2024
Home BUSINESSParas, Novozymes team up to better osteoporosis treatment
Print
« Previous News
Thu, 26 Nov, 2015 03:30:35 AM
FTimes Report, Nov 26

Paras Biopharmaceuticals of Finland has teamed up with Novozymes Biopharma of Denmark to generate a ‘once-a-week’ biobetter of Teriparatide, a leading treatment for the debilitating bone disease osteoporosis that largely affects people over the age of 50.

“The collective technical expertise of Paras and Novozymes will bring solutions and treatment options for further convenience of osteoporosis patients,” maintained Dr Hans Söderlund, the director of Global Strategic Alliance at Paras Biopharmaceuticals Finland Oy, in a company press release.

The partnership is aimed at developing a better version of Teriparatide so that the client can take injection of the medicine once a week or once every two weeks instead of the daily injection currently administered.

Osteoporosis is a major public health threat for an estimated 200 million women worldwide by weakening bones and increasing the risk of sudden and unexpected fractures. One in three women and one in five men over the age of 50 will break a bone due to osteoporosis in their lifetime.

“Novozymes’ VELTIS technology and Paras Biopharmaceuticals’ DiabridNobleCleav technology will create a superior osteoporosis medicine,” maintained Dr Ashesh Kumar, the Biologics and Licensing director at Paras.

Based in Oulu, Paras is an award winning, privately-held Finnish company focused on developing biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. The company has already developed a highly efficient production technology platform for the biosimilar of Recombinant Teriparatide (Forteo Biosimilar). Extending the release of its base molecule to once-a-week by incorporating Novozymes’ VELTIS technology will offer new and better solutions.

Novozymes is the world leader in biological solutions. It’s the world’s largest provider of enzyme and microbial technologies. Already well-established in the fields of diabetes, hemophilia and neutropenia, Novozymes’ VELTIS platform is able to provide once-weekly, once bi-weekly or once-monthly peptide or protein dosing. As a result, VELTIS offers the potential for enhanced patient adherence and improved therapeutic impact.

“This is a further market validation of the Novozymes Biopharma’s VELTIS technology,” said Novozymes Biopharma Director Svend Licht, commenting on the partnership deal. “We are happy to enable the development of this biobetter, this in addition to running numerous collaborations in life cycle management and new drug candidates”.

Novozymes is working together with a number of pharma companies who are exploring the possibilities of VELTIS as a platform for half-life extension. These companies include CSL and EpiVaX while GlaxoSmithKline is using VELTIS in a marketed drug for treatment of diabetes.

« Previous News
comments powered by Disqus
More News

 
   
Copyright © 2024 All rights reserved
Developed By -